03 May 2019
Visiongain has launched a new pharma report Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies.
The anti-cancer drugs market will continue to increase over the next 10 years, as the incidence of cancer rises around the world. Growth will be driven by the ageing population in both the developed and developing markets. Better accessibility to healthcare and new diagnostic techniques has allowed more cancer cases to be discovered when they can be more easily treated. Continuous research and development will lead to more treatments being available on the market, although the number of big blockbuster drugs will fall as treatment becomes more personalised.
The lead analyst of the report commented "The cancer treating drugs market will continue to grow over the next ten years. Despite generic erosion due to patent expiry on some leading anti-cancer drugs, this market will gain successful new products, including orphan drugs for rare cancers. Many R&D studies focus on immunotherapy and targeted therapy, in line with the increasing interest in personalised medicine."
Leading companies featured in the report include Abbott Laboratories, AbbVie, Amgen, Astellas Pharma, AstraZeneca, Aurora Biophama, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Celgene Corporation, Eli Lilly, Fresenius Kabi and other companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.
21 June 2019
There is an increasing focus to identify diseases that currently do not have a vaccine.
20 June 2019
The market for ophthalmic drugs is a growing one.